These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24616701)

  • 1. The role of iron in anthracycline cardiotoxicity.
    Gammella E; Maccarinelli F; Buratti P; Recalcati S; Cairo G
    Front Pharmacol; 2014; 5():25. PubMed ID: 24616701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
    Simůnek T; Stérba M; Popelová O; Adamcová M; Hrdina R; Gersl V
    Pharmacol Rep; 2009; 61(1):154-71. PubMed ID: 19307704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
    Ghigo A; Li M; Hirsch E
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine.
    Cheah IK; Tang RMY; Wang X; Sachaphibulkij K; Chong SY; Lim LHK; Wang JW; Halliwell B
    Antioxidants (Basel); 2023 Jan; 12(2):. PubMed ID: 36829879
    [No Abstract]   [Full Text] [Related]  

  • 5. [The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity].
    Dudka J
    Postepy Hig Med Dosw (Online); 2006; 60():241-7. PubMed ID: 16641894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of anthracycline cardiotoxicity by iron chelation.
    Hershko C; Pinson A; Link G
    Acta Haematol; 1996; 95(1):87-92. PubMed ID: 8604592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction.
    Link G; Tirosh R; Pinson A; Hershko C
    J Lab Clin Med; 1996 Mar; 127(3):272-8. PubMed ID: 9273360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect.
    Huang J; Wu R; Chen L; Yang Z; Yan D; Li M
    Front Pharmacol; 2022; 13():811406. PubMed ID: 35211017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoprotective agents for anthracyclines.
    Dorr RT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of iron and iron chelators in anthracycline cardiotoxicity.
    Hershko C; Link G; Tzahor M; Pinson A
    Leuk Lymphoma; 1993 Oct; 11(3-4):207-14. PubMed ID: 8260895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
    Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
    Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pharmacology of the interaction of anthracyclines with iron.
    Xu X; Persson HL; Richardson DR
    Mol Pharmacol; 2005 Aug; 68(2):261-71. PubMed ID: 15883202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
    Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
    Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human heart cytosolic reductases and anthracycline cardiotoxicity.
    Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
    IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.
    Varghese SS; Eekhoudt CR; Jassal DS
    Mol Cell Biochem; 2021 Aug; 476(8):3099-3109. PubMed ID: 33835331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rac1-mediated cardiac damage causes diastolic dysfunction in a mouse model of subacute doxorubicin-induced cardiotoxicity.
    Ohlig J; Henninger C; Zander S; Merx M; Kelm M; Fritz G
    Arch Toxicol; 2018 Jan; 92(1):441-453. PubMed ID: 28710503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity of anthracycline therapy: current perspectives.
    Valcovici M; Andrica F; Serban C; Dragan S
    Arch Med Sci; 2016 Apr; 12(2):428-35. PubMed ID: 27186191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.